The G-BA Innovation Committee recommends transfer to standard care for another three completed projects in Germany

In late June – mid-July 2024, the Innovation Committee at the Federal Joint Committee (G-BA) published the decisions recommending the transfer to standard care for another three completed projects. The projects were dedicated to the topics of care concept for patients with hidradenitis suppurativa (acne inversa), the use of webcams in neonatal intensive care units, and improving the pharmacovigilance of innovative therapies.

The “EsmAiL - Evaluation of a structured and guideline-based multimodal care concept for people with hidradenitis suppurativa (acne inversa)” project initiated the creation of acne inversa centers nationwide. The patients were managed according to a structured treatment plan based on current clinical guidelines and scientific findings. The project results will be forwarded to the G-BA, which will be requested to examine how they can be incorporated into its ongoing consultations on a new treatment method for acne inversa. In addition, the Association of the Scientific Medical Societies (AWMF) will be asked to provide feedback on whether the project results can be considered in the design and further development of corresponding clinical guidelines.

The healthcare research project “Neo-CamCare - Use of webcams in neonatal intensive care units (NICU)” evaluated the use of webcams in NICU from the perspective of the parents and the medical and nursing staff. Most parents rated the webcams helpful and felt more reassured by using them. The project also demonstrated that using webcams does not lead to an increased workload for the responsible staff and is also a viable concept from a legal point of view. Against this background, the Innovation Committee is forwarding the results achieved in the project to the Society for Neonatology and Pediatric Intensive Care Medicine and the German Society for Gynecology and Obstetrics for information.

The analysis performed within the “VerSI-MS-PV - Making care safe - Feasibility study on the suitability of various data sources as a basis for improving the pharmacovigilance of innovative therapies using multiple sclerosis (MS) as an example” project combined billing data from 44 sickness funds and 12 associations of statutory health insurance physicians with data from two MS patient registers and the Paul Ehrlich Institute's spontaneous reporting system. The project's results demonstrated that data on side effects from standard care can usefully supplement the Paul Ehrlich Institute's spontaneous reporting system and improve drug safety. The documentation platform established for this purpose within the MS register for the collection of patient data will be continued beyond the end of the project so that register-based pharmacovigilance data on MS can be further evaluated and communicated in line with the specified reporting channels.

The full details in German can be found here, here, here (EsmAiL project), here (Neo-CamCare project), and here (VerSI-MS-PV project).

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.